Cargando…

Patterns of Tyrosine Kinase Inhibitor Utilization in Newly Treated Patients With Chronic Myeloid Leukemia: An Exhaustive Population-Based Study in France

We analyzed demographic characteristics, comorbidities and patterns of treatment with tyrosine kinase inhibitors (TKIs) in a cohort of 3,633 incident cases of chronic myeloid leukemia (CML) identified across France from 1 January 2011 to 31 December 2014. Patients were identified through a specific...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pajiep, Marie, Conte, Cécile, Huguet, Françoise, Gauthier, Martin, Despas, Fabien, Lapeyre-Mestre, Maryse
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515137/ https://www.ncbi.nlm.nih.gov/pubmed/34660261 http://dx.doi.org/10.3389/fonc.2021.675609

Ejemplares similares

Identifying multiple myeloma patients using data from the French health insurance databases: Validation using a cancer registry
por: Palmaro, Aurore, et al.
Publicado: (2017)

A novel approach for medical research on lymphomas: A study validation of claims-based algorithms to identify incident cases
por: Conte, Cécile, et al.
Publicado: (2018)

Vaccination during the First Diagnosis of Multiple Myeloma: A Cohort Study of the French National Health Insurance Database
por: Tournaire, Guilhem, et al.
Publicado: (2020)

Ambulatory Medical Assistance - After Cancer (AMA-AC): A model for an early trajectory survivorship survey of lymphoma patients treated with anthracycline-based chemotherapy
por: Compaci, Gisèle, et al.
Publicado: (2015)

Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database
por: Berthet, Stephanie, et al.
Publicado: (2011)

Drug–drug interactions with imatinib: An observational study
por: Récoché, Isabelle, et al.
Publicado: (2016)

Gabapentinoid Abuse in France: Evidence on Health Consequences and New Points of Vigilance
por: Tambon, Marine, et al.
Publicado: (2021)

Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors
por: Etienne, Gabriel, et al.
Publicado: (2019)

Misuse and Dependence on Non-Prescription Codeine Analgesics or Sedative H1 Antihistamines by Adults: A Cross-Sectional Investigation in France
por: Roussin, Anne, et al.
Publicado: (2013)

Novel forms of injectable buprenorphine and French model of opioid use disorder treatment
por: Lapeyre-Mestre, Maryse
Publicado: (2020)

Considering sex-specific adverse drug reactions should be a priority in pharmacovigilance and pharmacoepidemiological studies
por: Lapeyre-Mestre, Maryse
Publicado: (2019)

Addictovigilance contribution during COVID-19 epidemic and lockdown in France
por: Lapeyre-Mestre, Maryse, et al.
Publicado: (2020)

Unfolding tyrosine kinase inhibitor sensitivity in chronic myeloid leukemia
por: Perrotti, Danilo, et al.
Publicado: (2012)

Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors
por: Haznedaroğlu, İbrahim C.
Publicado: (2013)

Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
por: Tiribelli, Mario, et al.
Publicado: (2019)

Novel Tyrosine Kinase Inhibitors to Target Chronic Myeloid Leukemia
por: Ciaffaglione, Valeria, et al.
Publicado: (2022)

Long-term outcome of tyrosine kinase inhibitor treatment in children and adolescents with newly diagnosed chronic myeloid leukemia in chronic phase
por: Zheng, Yong-Zhi, et al.
Publicado: (2021)

Tyrosine kinase inhibitors induced immune thrombocytopenia in chronic myeloid leukemia?
por: Barak, Avital F., et al.
Publicado: (2011)

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia
por: Kentsis, Alex, et al.
Publicado: (2012)

When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
por: Laneuville, Pierre
Publicado: (2018)

Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
por: García-Gutiérrez, Valentín, et al.
Publicado: (2019)

Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?
por: Fernandez, Solène, et al.
Publicado: (2019)

Patient-Initiated Discontinuation of Tyrosine Kinase Inhibitor for Chronic Myeloid Leukemia
por: Langabeer, Stephen E., et al.
Publicado: (2020)

WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors
por: Haznedaroğlu, İbrahim C., et al.
Publicado: (2020)

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?
por: Atallah, Ehab, et al.
Publicado: (2020)

Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia
por: Kim, Yundeok, et al.
Publicado: (2021)

Aortic Stenosis and the Tyrosine Kinase Inhibitor Nilotinib in Chronic Myeloid Leukemia
por: Carracedo, Miguel, et al.
Publicado: (2020)

Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia
por: Pokorny, Rebecca, et al.
Publicado: (2022)

Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia
por: Pasvolsky, Oren, et al.
Publicado: (2015)

Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype
por: Harrington, Patrick, et al.
Publicado: (2022)

Laboratory Monitoring of Patients Treated with Antihypertensive Drugs and Newly Exposed to Non Steroidal Anti-Inflammatory Drugs: A Cohort Study
por: Fournier, Jean-Pascal, et al.
Publicado: (2012)

Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy
por: DeAngelo, D J
Publicado: (2012)

Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors Treatment
por: Wieczorek, Agnieszka, et al.
Publicado: (2016)

BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
por: Cuellar, Sandra, et al.
Publicado: (2017)

Recurrent ventricular fibrillation with different tyrosine kinase inhibitors for chronic myeloid leukemia
por: Prashar, Abhisheik, et al.
Publicado: (2020)

Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations
por: Abruzzese, Elisabetta, et al.
Publicado: (2020)

MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia
por: Morales, María Luz, et al.
Publicado: (2019)

Current Views on the Interplay between Tyrosine Kinases and Phosphatases in Chronic Myeloid Leukemia
por: Boni, Christian, et al.
Publicado: (2021)

The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia
por: Saydam, Guray, et al.
Publicado: (2022)

Cross-national health care database utilization between Spain and France: results from the EPICHRONIC study assessing the prevalence of type 2 diabetes mellitus
por: Moulis, Guillaume, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_oegu8aeb0aufe013tqbdpnb5i6